Page 18 of 25

PA27.3-4 | Acute & Chronic Renal Failure — SDL Guide (Part 4)

AKI vs CKD — Distinguishing Features

Side-by-side educational diagram comparing AKI and CKD by onset, previous creatinine, kidney size, anaemia, calcium, and PTH changes.

AKI vs CKD: Distinguishing Features

Panel A: AKI: normal-to-enlarged kidneys; onset days to weeks; previous creatinine normal baseline; anaemia mild or absent early; calcium usually normal; PTH normal.. Panel B: CKD: small contracted kidneys; onset months to years with ≥3 months criterion; previous creatinine elevated on prior records; severe normocytic normochromic anaemia; calcium decreased; PTH increased; renal osteodystrophy; exceptions include DM, PKD, and amyloid..

Distinguishing AKI from CKD at presentation is a critical clinical-pathological skill:

FeatureAKICKD
OnsetDays to weeksMonths to years (≥3 months criterion)
Previous creatinineNormal baselineElevated on prior records
Kidney size (USS)Normal to enlargedSmall, contracted (except DM, PKD, amyloid)
AnaemiaMild or absent (early)Severe normocytic normochromic
CalciumUsually normal↓ (renal osteodystrophy)
PTHNormal↑ (secondary hyperparathyroidism)
Nails/neuropathyAbsentMees' lines, peripheral neuropathy
Renal biopsyTubular necrosis; recoverableGlomerulosclerosis, fibrosis, atrophy — irreversible
ReversibilityPotentially full recoveryIrreversible; progressive

Important: AKI on CKD — a patient with pre-existing CKD may develop an acute insult (dehydration, sepsis, contrast) that worsens GFR acutely. Treating the acute component may restore to the CKD baseline (not normal). Always look for a reversible precipitant.

Management principles (brief):
- AKI: treat the cause (fluids for prerenal; remove nephrotoxins), prevent complications, renal replacement therapy (RRT) if AEIOU criteria met.
- CKD: slow progression (RAAS blockade, BP control, glycaemic control), manage complications (EPO for anaemia, vitamin D analogues + phosphate binders for bone disease, dietary K⁺/phosphate restriction), plan for RRT (haemodialysis, peritoneal dialysis, or transplant — the curative option).

⚑ AI image — pending faculty review (auto-QA score 7/10; best of 3 attempts)

Side-by-side infographic comparing AKI and CKD by kidney size, disease timeline, urine output pattern, laboratory findings, and end-stage CKD clinical clues.

AKI vs CKD: Morphology, Timeline, Urine Output, and Labs

Panel A: AKI column showing normal or enlarged smooth kidney, abrupt timeline, variable urine output, acute creatinine rise, initially normal haemoglobin, near-normal PTH, and near-normal calcium.. Panel B: CKD column showing small contracted granular kidney, long chronic timeline, early nocturia/polyuria with late oliguria, chronically high creatinine, low haemoglobin from decreased EPO, high PTH, and low or normal-low calcium.. Bottom banner: Clinical end-stage CKD clue showing bilateral 7.5 cm granular kidneys with thin cortices, Hb 7.0 g/dL, PTH 380 pg/mL, and management goal of slowing progression, treating uraemic complications, and planning dialysis or transplant..

SELF-CHECK

Ultrasound of a patient with renal failure shows both kidneys measuring 7.5 cm with granular surfaces and markedly thinned cortices. Haemoglobin is 7.0 g/dL, PTH is 380 pg/mL. Which diagnosis is most consistent, and what is the primary management goal?

A. AKI due to ATN; aggressive fluid resuscitation

B. Prerenal AKI; IV fluid challenge and recheck creatinine

C. Chronic kidney disease (likely end-stage); slow progression and plan renal replacement therapy

D. Polycystic kidney disease; genetic counselling

Reveal Answer

Answer: C. Chronic kidney disease (likely end-stage); slow progression and plan renal replacement therapy

Small contracted granular kidneys + severe anaemia (normocytic, ↓EPO) + markedly elevated PTH (secondary hyperparathyroidism from ↓vitamin D) are the classical triad of end-stage CKD. In AKI, kidneys are normal or enlarged and anaemia/osteodystrophy are absent or mild. PKD kidneys are massively enlarged, not contracted. Management now shifts to slowing any residual progression, managing uraemic complications, and planning haemodialysis/peritoneal dialysis or transplant referral.